Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Stage II, III
Nasopharyngeal Squamous Cell Carcinoma
Induction Chemotheray
Concurrent Chemoradiotherapy
Reduce Treatment Intensity

Interventions: Drug: Docetaxel
Radiation: IMRT
Drug: Cisplatin

First Posted Date: 2019-04-09

Last Posted Date: 2021-01-29

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 120

Registration Number: NCT03908372

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijin, China

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Metastatic Pancreatic Cancer
Pancreatic Cancer
Pancreas Cancer
Pancreatic Adenocarcinoma Resectable
Pancreatic Metastasis
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Ascorbic Acid
Drug: Paclitaxel protein-bound
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2019-04-09

Last Posted Date: 2019-05-30

Lead Sponsor: Medical College of Wisconsin

Registration Number: NCT03908333

Locations: 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
University of California San Diego Moores Cancer Center, San Diego, California, United States

and more 1 locations

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Nivolumab
Drug: Cisplatin
Drug: Docetaxel
Radiation: Intensity-modulated radiotherapy

First Posted Date: 2019-03-29

Last Posted Date: 2023-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT03894891

Locations: 🇺🇸
The Tisch Cancer Institute, New York, New York, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 1 locations

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

Phase 2

Terminated

Conditions: Lung Adenocarcinoma

Interventions: Drug: L-DOS47
Drug: Cisplatin
Drug: Vinorelbine

First Posted Date: 2019-03-26

Last Posted Date: 2022-08-12

Lead Sponsor: Helix BioPharma Corporation

Target Recruit Count: 9

Registration Number: NCT03891173

Locations: 🇺🇦
Vinnytsya Regional Clinical Oncological Centre, Vinnytsia, Ukraine
🇵🇱
Europejskie Centrum Zdrowia Otwock, Otwock, Poland
🇺🇦
Sumy Regional Clinical Oncological Centre, Sumy, Ukraine

and more 1 locations

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Phase 3

Withdrawn

Conditions: Esophageal Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Drug: 5-FU

First Posted Date: 2019-03-19

Last Posted Date: 2020-02-11

Lead Sponsor: Merck Sharp & Dohme LLC

Registration Number: NCT03881111

Locations: 🇨🇳
Peking Union Medical College Hospital ( Site 0123), Beijing, Beijing, China
🇨🇳
Guangdong General Hospital ( Site 0103), Guangzhou, Guangdong, China
🇨🇳
The Affiliated Tumour Hospital of Harbin Medical University ( Site 0102), Harbin, Heilongjiang, China

and more 17 locations

Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)

Phase 2

Recruiting

Conditions: Peritoneal Mesothelioma
Peritoneal Carcinomatosis

Interventions: Procedure: PIPAC
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2019-03-14

Last Posted Date: 2024-01-17

Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

Target Recruit Count: 66

Registration Number: NCT03875144

Locations: 🇫🇷
Institut réginal du Cancer de Montpellier, Montpellier, France

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor
Colorectal Cancer
Gastric Cancer
Renal Cell Carcinoma
Melanoma
Epithelial Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
Cholangiocarcinoma
Bladder Cancer

Interventions: Biological: TRK-950
Drug: Irinotecan
Drug: Gemcitabine
Drug: Bevacizumab
Drug: PLD
Drug: Imiquimod Cream
Drug: Ramucirumab
Drug: Nivolumab
Drug: Leucovorin
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pembrolizumab
Drug: 5-FU

First Posted Date: 2019-03-13

Last Posted Date: 2024-08-02

Lead Sponsor: Toray Industries, Inc

Target Recruit Count: 187

Registration Number: NCT03872947

Locations: 🇺🇸
HOAG Memorial Hospital Presbyterian, Newport, California, United States
🇺🇸
Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Northwest Cancer Specialists, Portland, Oregon, United States

and more 11 locations

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma
Bladder Cancer

Interventions: Drug: Atezolizumab
Drug: Enfortumab Vedotin
Drug: Niraparib
Drug: Magrolimab (Hu5F9-G4)
Drug: Tiragolumab
Drug: Sacituzumab Govitecan
Drug: Tocilizumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2019-03-11

Last Posted Date: 2025-01-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 272

Registration Number: NCT03869190

Locations: 🇫🇷
Centre Francois Baclesse, Caen, France
🇬🇷
Attiko Hospital University of Athens, Athens, Greece
🇬🇷
Athens Medical Center, Athens, Greece

and more 30 locations

A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: CC-90011
Drug: Carboplatin
Drug: Nivolumab
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2019-02-21

Last Posted Date: 2024-08-26

Lead Sponsor: Celgene

Target Recruit Count: 90

Registration Number: NCT03850067

Locations: 🇪🇸
Local Institution - 406, Majadahonda, Madrid, Spain
🇫🇷
Local Institution - 102, Marseille Cedex 5, France
🇪🇸
Local Institution - 402, Barcelona, Spain

and more 10 locations

GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 3

Active, not recruiting

Conditions: Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms
Head and Neck Neoplasm
Nasopharyngeal Diseases

Interventions: Drug: gemcitabine and cisplatin
Drug: cisplatin and fluorouracil
Radiation: IMRT
Drug: cisplatin

First Posted Date: 2019-02-15

Last Posted Date: 2023-12-12

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 468

Registration Number: NCT03840421

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy